REVB
Revelation Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.01
+0.00%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
Market Cap
$4.02M
MomentumView details →
1D Return
+0.00%
YTD Return
−68.13%
RSI (14)
46.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.6x
Market Cap
$4.02M
RSI (14)
46.7
MomentumView details →
1D Return
+0.00%
YTD Return
−68.13%
SummaryUpdated Jun 1, 2026
Revelation Biosciences, Inc. (NASDAQ:REVB) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in San Diego, California. The company went public in November 2020 and focuses on developing immune system therapeutics and diagnostics. As a relatively young biotech firm, Revelation operates without current revenue generation, dedicating its resources entirely to research and development of novel therapeutic candidates across multiple disease areas including respiratory conditions, chronic organ diseases, and infectious disease diagnostics.
Similar companies
Latest newsMore news →
Revelation Biosciences selected Avance Clinical as the contract research organization for its Phase 2/3 TITAN study evaluating Gemini in patients with acute kidney injury.16d agoRevelation Biosciences, Inc. granted restricted stock awards to CEO James Rolke and CFO Chester S. Zygmont III as part of their compensation.17d ago